Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Public Advisory - Unauthorized health products seized from Tokyo Beauty and Healthcare store in Richmond, B.C., may pose serious health risks


      News provided by

      Health Canada (HC)

      Mar 08, 2024, 09:45 ET

      Share this article

      Share this article


      OTTAWA, ON, March 8, 2024 /CNW/ - UPDATE: March 8, 2024: Additional unauthorized health products seized from another Tokyo Beauty and Healthcare store in Richmond, B.C.

      Further to its communication on September 18, 2023, Health Canada is warning consumers about additional unauthorized health products seized from another Tokyo Beauty and Healthcare store located at Unit 3660 - 4151 Hazelbridge Way, Richmond, B.C. These products are labelled to contain prescription, controlled, or over-the-counter drugs, and may pose serious health risks.

      Pabron Gold A Granules Cold Medication (CNW Group/Health Canada (HC))
      Pabron Gold A Granules Cold Medication (CNW Group/Health Canada (HC))
      Pair Acne Cream (CNW Group/Health Canada (HC))
      Pair Acne Cream (CNW Group/Health Canada (HC))
      Mentholatum Mediquick Eczema Rash Anti-Itch Ointment (CNW Group/Health Canada (HC))
      Mentholatum Mediquick Eczema Rash Anti-Itch Ointment (CNW Group/Health Canada (HC))
      Hadalabo Pearl Barley Face Wash (CNW Group/Health Canada (HC))
      Hadalabo Pearl Barley Face Wash (CNW Group/Health Canada (HC))
      Santen Sante Beauteye Moon Care (CNW Group/Health Canada (HC))
      Santen Sante Beauteye Moon Care (CNW Group/Health Canada (HC))
      Pabron Gold A Granules Cold Medication (CNW Group/Health Canada (HC)) Pair Acne Cream (CNW Group/Health Canada (HC)) Mentholatum Mediquick Eczema Rash Anti-Itch Ointment (CNW Group/Health Canada (HC)) Hadalabo Pearl Barley Face Wash (CNW Group/Health Canada (HC)) Santen Sante Beauteye Moon Care (CNW Group/Health Canada (HC))

      The list of products seized has been added to the Affected Products table below. Information on the health risks associated with these drugs as well as information for consumers can be found further below.

      Original Advisory: September 18, 2023: Unauthorized health products seized from a Tokyo Beauty and Healthcare store in Richmond, B.C., may pose serious health risks

      Product: Unauthorized health products labelled to contain prescription, controlled or over-the-counter drugs
      Issue: Health products - Product safety
      What to do: Do not use these products. Buy your prescription drugs only from licensed pharmacies. Return products to your local pharmacy for proper disposal. Consult a health care professional if you have used any of these products and have health concerns. One of the products (Pabron Gold A Granules Cold Medication) contains an opioid. If you suspect an opioid overdose, call 911 and administer naloxone if available.

      Issue

      Health Canada is warning consumers about unauthorized health products it seized from a Tokyo Beauty and Healthcare store in Richmond, B.C. (120 - 8191 Westminster Highway). The products are labelled to contain prescription, controlled or over-the-counter drugs and may pose serious health risks.

      Selling unauthorized health products in Canada is illegal. Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks. For example, they could contain high-risk ingredients, such as prescription drugs, additives or contaminants that may or may not be listed on the label. These ingredients could interact with other medications and foods. In addition, these products may not actually contain the active ingredients that consumers would expect them to contain to help maintain and improve their health.

      Prescription drugs should only be used under the advice and supervision of a health care professional because they are used to treat specific conditions and may cause serious side effects. Prescription drugs can only be legally sold to consumers in Canada with a prescription.

      Affected products

      Product

      Promoted use

      Drug on the label

      Tokyo Beauty and Healthcare store

      Pabron Gold A Granules Cold Medication

      Relieve cold symptoms

      Labelled to contain dihydrocodeine phosphate

      120 - 8191 Westminster Highway, Richmond, B.C.

      Kobayashi Pharmaceutical Faichi Iron + Folic Acid + Vitamin B12 Blood Supplement Tablets

      Aid production of blood hemoglobin and improve anemia

      Labelled to contain prescription-strength folic acid

      120 - 8191 Westminster Highway, Richmond, B.C.

      Mentholatum Mediquick Eczema Rash Anti-Itch Cream

      Eczema and rash relief

      Labelled to contain prednisolone valerate acetate

      120 - 8191 Westminster Highway, Richmond, B.C.

      Mentholatum Mediquick Eczema Rash Anti-Itch Ointment

      Eczema and rash relief

      Labelled to contain prednisolone valerate acetate

      120 - 8191 Westminster Highway, Richmond, B.C.

      Nichiban Speel Ko One-touch EX

      Corns, callus and wart removal

      Labelled to contain salicylic acid

      120 - 8191 Westminster Highway, Richmond, B.C.

      Ohta's Isan A

      Aid digestion and relieve heartburn

      Labelled to contain ursodeoxycholic acid

      120 - 8191 Westminster Highway, Richmond, B.C.

      Santen Beauteye Contact

      Eye fatigue

      Labelled to contain neostigmine methylsulfate

      120 - 8191 Westminster Highway, Richmond, B.C.

      Santen PC Eyedrops

      Eye inflammation and fatigue

      Labelled to contain neostigmine methylsulfate

      120 - 8191 Westminster Highway, Richmond, B.C.

      Smile 40EX Gold Cool MAX

      Eye fatigue, blurred vision

      Labelled to contain neostigmine methylsulfate

      120 - 8191 Westminster Highway, Richmond, B.C.

      Santen Sante Beauteye Moon Care

      Prevention of eye disease, conjunctival congestion, bleary eyes

      Labelled to contain aminocaproic acid

      Unit 3660 - 4151 Hazelbridge Way, Richmond, B.C.

      Pair Acne Cream

      Acne skin treatment

      Labelled to contain ibuprofen piconol 3%

      Unit 3660 - 4151 Hazelbridge Way, Richmond, B.C.

      Pabron Gold A Granules Cold Medication

      Relieve cold symptoms

      Labelled to contain dihydrocodeine phosphate

      Unit 3660 - 4151 Hazelbridge Way, Richmond, B.C.

      Mentholatum Mediquick Eczema Rash Anti-Itch Ointment

      Eczema and rash relief

      Labelled to contain prednisolone valerate acetate

      Unit 3660 - 4151 Hazelbridge Way, Richmond, B.C.

      Hadalabo Pearl Barley Face Wash

      Skin treatment

      Labelled to contain aminocaproic acid

      Unit 3660 - 4151 Hazelbridge Way, Richmond, B.C.

      What you should do
      • Do not use these products. Return the product to your local pharmacy for proper disposal.
      • Consult a health care professional if you have used any of these products and have health concerns.
      • Pabron Gold A Granules Cold Medication contains an opioid. Opioid overdose is a medical emergency that could lead to death if untreated. If you suspect an opioid overdose, call 911 and administer naloxone if available.
      • Buy your prescription drugs only from licensed pharmacies.
      • Read product labels to verify that health products have been authorized for sale by Health Canada. Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM). You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database.
      • Report any health product-related side effects or complaints to Health Canada.
      Additional information
      Background

      Aminocaproic acid is a prescription drug ingredient used to decrease bleeding in various clinical situations. Exposure to aminocaproic acid in the eye may affect the eye itself, and the acid may be absorbed through the tear ducts into the blood. Side effects may include watery eyes, vision changes, headache, dizziness, nausea, muscle weakness and skin rash.

      Dihydrocodeine phosphate is a controlled substance regulated under the Controlled Drugs and Substances Act and is similar to the opioid codeine. Although codeine is approved in Canada, Health Canada has not authorized any drug products containing dihydrocodeine. Dihydrocodeine tablets are approved in certain countries for the relief of severe and chronic pain or as cough suppressants. Common adverse reactions include dizziness, headache, vertigo, visual disturbances, confusion, euphoria, nausea, and constipation. As with all opioids, use of dihydrocodeine may lead to drug dependence (addiction). Dihydrocodeine may cause slowed or stopped breathing, which can lead to severe drowsiness, unconsciousness, and death (opioid overdose). People with other medical conditions, including but not limited to those that affect the lungs, liver or kidney, may be at a higher risk of overdose. Children are more susceptible to overdose due to their smaller size. Dihydrocodeine should not be used by those who are pregnant or breastfeeding, or by those with an allergy to dihydrocodeine. Using dihydrocodeine with other central nervous system depressants (e.g. alcohol, sleeping pills, etc.) may worsen its effects. In cases of overdose, naloxone can temporarily reverse the effects of dihydrocodeine.

      Folic acid tablets at strengths above 1 mg are prescription drugs available in Canada for the prevention and treatment of: folate deficiency, birth defects, and side effects related to methotrexate treatment. Folic acid should not be taken at doses of more than 1 mg per day without the advice of a health care professional. Taking too much folic acid may hide signs of a vitamin B12 deficiency and increase the risk of progressive, unrecognized neurological damage. Taking too much folic acid may also increase the risk of colorectal and possibly other cancers in certain individuals. High doses of folic acid might lead to symptoms, including loss of appetite, nausea, abdominal bloating, gas, bitter taste, changes to sleep, trouble concentrating, depression, impaired judgement, and feeling irritable, excited, overactive or confused. Rare but serious side effects include severe allergic reactions. Folic acid should not be used by people who have untreated vitamin B12 deficiency. Oral folic acid is not to be used by people who have diseases of the small intestine, especially Crohn's disease and celiac disease, due to difficulties absorbing folic acid.

      Ibuprofen piconol 3% is a topical (applied to the skin) non-steroidal anti-inflammatory drug (NSAID) used to relieve burns. Health Canada has not approved any drugs containing ibuprofen for topical use. Ibuprofen absorbed through the skin may cause side effects throughout the body, especially when used over a large surface area and for a long time, or on damaged skin. Topical ibuprofen may cause serious side effects in people who are allergic to ibuprofen, aspirin or other NSAIDs, or who are asthmatic. Use of topical ibuprofen may also cause serious side effects such as stomach and intestinal bleeding, renal (kidney) dysfunction or failure, or cardiovascular dysfunction or failure in people who have problems with these organs. Topical ibuprofen can also cause serious side effects in people who are pregnant or breastfeeding, such as delayed and increased duration of labour.

      Neostigmine methylsulfate is a prescription drug available in Canada as an injection used to prevent and treat urine retention and intestinal complications after surgery, to reverse the paralyzing effect of certain drugs used in surgery and in shock therapy, and to control symptoms of myasthenia gravis (a disease that causes weakness in the skeletal muscles). It has not been approved for use as eye drops in Canada. In the past, drugs similar to neostigmine were used to treat glaucoma, a group of eye diseases traditionally characterized by elevated pressure within the eye. These medications are no longer widely used because of the significant number of potential eye-related side effects, including blurred distance vision, frontal headaches, twitching lids, red eyes, cataracts (clouding of the normally clear lens of the eye), allergic reactions, iris cysts, retinal detachment with symptoms of reduced vision, sudden appearance of flashes of light or floaters that could lead to permanent vision loss, and the potential for causing a specific type of glaucoma attack with potential permanent vision loss. In addition, absorption into the nose via the tear duct may cause serious cardiac and respiratory side effects.

      Prednisolone valerate acetate is a prescription corticosteroid drug available in Canada as eye drops used to treat inflammation of several parts of the eye. It has not been approved for use in creams or ointments in Canada. Common side effects for topical corticosteroids include skin atrophy (thin and fragile skin with reduced elasticity), skin blood vessel changes (e.g., spider veins), change in skin color, stretch marks, swelling, dry skin, burning sensation, local irritation, rash, redness, itching, thinning hair or excessive hair growth, infections and allergic reactions. Topical corticosteroids absorbed through the skin may cause side effects throughout the body, especially when used over a large surface area and for a long time. This risk is greater in children, who may absorb proportionally larger amounts and be more susceptible to side effects. Systemic side effects could include high blood pressure, high blood sugar, blurred vision, uneven heartbeats, weakness, and swelling. Prednisolone acetate should not be used in patients who are allergic to prednisolone acetate or to any ingredient in the formulation. Prednisolone acetate is not to be used in children and is not recommended for use during pregnancy or breastfeeding.

      Salicylic acid is a prescription drug when sold for topical uses at concentrations greater than 20% or with a certain level of acidity (pH less than 3.0) except when sold to be applied to warts, corns or calluses. It is also used to treat acne. It should not be used by people who are allergic to salicylic acid, by people with diabetes, poor circulation, loss of sensation in the extremities (e.g., hands and feet), or by children and teenagers with the flu or chicken pox (as it may increase the risk of Reye's syndrome, a serious disease that might lead to seizures and coma). It should not be used by pregnant or nursing people unless the area of exposure and duration of therapy is limited. Some products containing salicylic acid should not be used in children younger than two years of age. Salicylic acid can cause serious allergic reactions (hives, itching, trouble breathing, and swelling of the face, lips, or tongue), and severe skin irritation (redness, burning, dryness, itching, and peeling). It can also cause salicylate toxicity, a serious condition with nausea, vomiting, dizziness, loss of hearing, ringing in the ears, diarrhea, confusion, rapid breathing, and drowsiness. Side effects are more likely to occur in children and in people with kidney or liver disease, and with prolonged use over large areas. Salicylic acid should not be used on infected areas, on moles, birthmarks, warts with hair growing from them, or warts on the face.

      Ursodeoxycholic acid is a prescription drug used for the management of cholestatic liver diseases (diseases that involve blocked or reduced bile flow from the liver). Serious side effects of taking ursodeoxycholic acid include allergic reactions, chest pain and difficulty breathing, stomach ache, nausea, diarrhea or constipation, swelling of the extremities (e.g., hands and feet), high blood pressure, fatigue, dizziness, headache, itchiness, fever and jaundice. Some patients have experienced additional symptoms such as vomiting and pain in the abdominal area caused by blockages in the gastrointestinal tract, which requires medical intervention. Blood tests are needed to monitor for the risk of liver toxicity from taking this drug. Ursodeoxycholic acid should not be used by people who have an allergy to ursodiol, have a blockage of bile flow due to liver or other disease, or by people who are pregnant, planning to become pregnant, or breastfeeding.

                                                                        Également disponible en français

      SOURCE Health Canada (HC)

      Media Enquiries: Health Canada, (613) 957-2983, [email protected]; Public Enquiries: (613) 957-2991, 1-866 225-0709, [email protected]

      Modal title

      Organization Profile

      Health Canada (HC)

        Also from this source

      • Health Canada announces new supports to improve the health of Black Canadians

      • Multi-jurisdictional Measles Outbreak is Over

      • FPT Communiqué - Federal, Provincial and Territorial (FPT) Health Ministers' Meeting

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.